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PGD2 biosynthesis is augmented during 


























closely  resembled  that of urinary TxM,  consistent with both 
Figure 1
Human platelets generate PGD2, and PGD2 inhibits human platelet aggregation. (A) PGD2 was 
produced ex vivo by human platelets after aggregation stimulated by 10 μM ADP, 10 μM arachidonic 
acid (AA), 10 μM collagen (CA), and 10 μM thrombin receptor–activating peptide (TRAP), while pre-
treatment with 100 μM aspirin (ASA) for 10 minutes prior to addition of the platelet agonist completely 
suppressed production of PGD2 (n = 4 per group). (B) Urinary PGDM was suppressed by administra-
tion of 81 mg/d aspirin orally for 5 days (n = 17). Suppression of urinary PGDM attained after dosing 
on day 5 was sustained for the entire 24 hours (P < 0.001), consistent with a substantial contribution 
from anucleated platelets to this metabolite. Cre, creatinine. (C) Urinary dinor-TxM was suppressed 
by administration of 81 mg/d aspirin orally for 5 days (n = 17). Suppression of urinary dinor-TxM 
attained after dosing on day 5 was sustained for the entire 24 hours (P < 0.001), consistent with a 
dominant contribution from anucleate platelets to this metabolite. (D) Urinary PGIM was suppressed 
by administration of 81 mg/d aspirin orally for 5 days (n = 17). Suppression of urinary PGIM was 
sustained for only 4 hours after dosing on day 5 (P < 0.05), consistent with a dominant contribution 
from nucleated cells to this metabolite.
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DP1 activation restrains the hypertensive and aneurysmal responses to 

































































PGD2 biosynthesis is augmented during accelerated platelet-vascular interactions in humans. (A) Excretion of TxM in successive 6-hour urinary 
aliquots commencing 6 hours before PTCA. TxM excretion increased significantly in aspirin-allergic patients (n = 3; P < 0.05). Pretreatment with 
aspirin at either 81 mg/d (n = 3) or 325 mg/d (n = 17) in patients for a minimum of 5 days before the procedure suppressed TxM (P < 0.001) 
and prevented the procedure-related increase in TxM during PTCA (P < 0.001). (B) Excretion of PGDM in successive 6-hour urinary aliquots 
commencing 6 hours before PTCA. PGDM excretion increased significantly in aspirin-allergic patients (n = 3; P < 0.05). Pretreatment with 
aspirin (ASA) at either 81 mg/d (n = 3) or 325 mg/d (n = 17) in control patients for a minimum of 5 days before the procedure suppressed PGDM 
(P < 0.001) and prevented the increase in PGDM during PTCA (P < 0.001). (C) Excretion of PGIM in successive 6-hour aliquots commencing 
6 hours before PTCA. Pretreatment with 325 mg aspirin reduced PGIM significantly in control patients before and during PTCA (P < 0.01); how-
ever, 81 mg/d aspirin had no significant effect on urinary PGIM. While urinary PGIM increased significantly during PTCA only in the control group 
(P < 0.05), there was a significant difference (P < 0.05) among the 3 groups with respect to procedure-related maximal urinary PGIM values.
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DP1 deletion augments Ang II–induced aneu-
rysm formation. (A) Representative images 
of abdominal aortas after 28 days of Ang II 
infusion. dKO, double KO. Scale bars: 1 mm. 
Abdominal aorta wet weights (B) and the outer 
diameter of abdominal aortas (C) were both 
significantly increased in DP1-ApoE double KO 
versus ApoE KO mice (n = 18–21; *P < 0.05). 
Each data point represents measurement from 
an individual mouse aorta displaying inter-
group variation. The horizontal bars represent 
mean ± SEM within each group. (D) Distribu-
tion of median AAA severity within both groups 
(n = 18–21), as classified previously (57).
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Niacin-induced stimulation of PGD2 



















an  increase  in TxB2  (Figure  7,  E 
































PGD2 restrains thrombogenesis in mice. (A and B) DP1 deletion short-
ened the mean time to 50% and 100% vascular occlusion of the carotid 
artery in female mice (n = 16–18; *P < 0.05). (C and D) No effect on 
thrombogenesis was evident in male mice (n = 15–18).
Figure 5
Expression of DP1 in atherosclerotic lesions of LDL receptor KO mice. Staining of atherosclerotic 
lesions in the (A) aortic root and (B) coronary artery with isotype control, anti-DP1, anti–VCAM-1, and 
anti-CD11b. Images were composited from approximately 20 images taken with a ×20 objective. Shown 
are representative composite images (n = 6). Scale bar: 300 μm.
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Here  we  present  evidence  that 
PGD2 is formed by platelet COX-1 

















































Niacin evokes platelet PGD2 biosynthesis in humans. Healthy volunteers received placebo or 81 mg 
aspirin each for 5 days, then 600 mg niacin (NA) was administered either 30 minutes (day 5 NA; 
n = 9) or 24 hours (day 6 NA; n = 6) after the last dose. Niacin evoked a significant increase in 
excretion of all prostanoid metabolites under placebo-treated conditions (P < 0.001). Administration 
of aspirin suppressed excretion of all metabolites when niacin was administered 30 minutes after 
the last aspirin dose, but only suppressed urinary PGDM and TxM significantly when administered 
24 hours after the last dose (P < 0.001).
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Figure 7
Stimulation of PGD2 release restrains activation of human platelets by niacin. While niacin did not alter generation of TxB2 or PGD2 by human 
platelets in PRP under basal conditions (A and B; n = 4), formation of both eicosanoids was significantly increased in a dose-dependent man-
ner by niacin when it was preincubated with platelets that were then stimulated with 10 μM ADP in PRP (C and D; n = 4). The trivial amount of 
PGD2 formed in WPs was unaltered by niacin, whereas niacin again significantly increased TxB2 formation (E and F; n = 4). Addition of 100 μM 
niacin to PRP did not alter platelet spreading, either with or without subsequent induction of spreading by stimulation with 40 μM ADP (G and H; 
n = 3). However, ADP-induced (40 μM) WP spreading was significantly augmented by preincubation with niacin (I and J; n = 4). Scale bars: 
20 μm. *P < 0.05; **P < 0.01; ***P < 0.001.
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